Study guide

15.2 QAPI Programs, PDSA Cycles & the ESRD Quality Incentive Program

Board Certified Specialist in Renal Nutrition CSR

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Kidney Disease Foundations

1.1 CDR CSR Exam Structure, Eligibility, Logistics & the 2023 Content Outline 1.2 Renal Anatomy, Physiology & Glomerular Hemodynamics 1.3 CKD Etiology, KDIGO Staging & Progression Risk

2 Chapter 2: Domain 1 — Anthropometric & Body Composition Assessment

2.1 Dry Weight Determination, Fluid Assessment & Interdialytic Weight Gain 2.2 Anthropometric Measurement Standards (Knee Height, Skinfolds, Frame Size) 2.3 Body Composition Analysis: BIA, BIS, DXA & Handgrip Dynamometry

3 Chapter 3: Domain 1 — Nutrition-Focused Physical Findings & PEW Assessment Tools

3.1 Protein-Energy Wasting (PEW) Diagnostic Criteria & Pathophysiology 3.2 Subjective Global Assessment (7-Point SGA) in Dialysis 3.3 Malnutrition Inflammation Score (MIS) & Scoring Protocols 3.4 Nutrition-Focused Physical Exam (NFPE) for Muscle & Fat Loss

4 Chapter 4: Domain 1 — Diet, Medical, Medication & Psychosocial History

4.1 Dietary Intake Assessment & Food Frequency Methods in CKD 4.2 Medical & Medication History: Drug–Nutrient Interactions and Supplements 4.3 Psychosocial, Social & Functional History in Renal Nutrition Assessment

5 Chapter 5: Domain 1 — Medical Tests & Procedures by Treatment Modality

5.1 Hemodialysis Clinical Assessment & Vascular Access Considerations 5.2 Peritoneal Dialysis & Peritoneal Glucose Absorption Assessment 5.3 AKI, CRRT & Pediatric Renal Disease Assessment

6 Chapter 6: Domain 1 — Nutrition Diagnosis: Terminology, Etiology & Reasoning

6.1 Standardized Nutrition Diagnostic Terminology (NCP) in Nephrology 6.2 Etiology & Root-Cause Analysis for Renal Nutrition Problems 6.3 Diagnostic Reasoning for Fluid, Mineral & Protein Imbalances

7 Chapter 7: Domain 1 — Nutrition Diagnosis in Complex Patients

7.1 Formulating Valid PES Statements in Complex Dialysis Patients 7.2 Differentiating PEW, Sarcopenia & Cachexia in CKD 7.3 Diagnostic Prioritization across Cardiorenal & Diabetic Nephropathy

8 Chapter 8: Domain 2 — Food & Nutrient Delivery: Protein & Energy

8.1 KDOQI 2020 Protein Targets: Non-Dialysis CKD (LPD vs. VLPD) 8.2 Protein Prescriptions for Hemodialysis and Peritoneal Dialysis 8.3 Energy Requirements, Carbohydrates & Plant-Dominant Diets (PLADO)

9 Chapter 9: Domain 2 — Electrolytes, Fluid, Acid–Base & Micronutrients

9.1 Potassium Management: Dietary Restriction, Leaching & K-Binders 9.2 Sodium & Fluid Prescriptions across Dialysis Modalities 9.3 Acid-Base Homeostasis & Bicarbonate Replacement Therapy 9.4 Micronutrient, Trace Mineral & Vitamin Supplementation in ESRD

10 Chapter 10: Domain 2 — Medications & Specialized Nutrition Support

10.1 CKD-MBD Pharmacology: Phosphorus Binders, Vitamin D & Calcimimetics 10.2 Anemia Management: Iron Homeostasis, IV Iron Protocols & ESAs 10.3 Enteral, IDPN & Intraperitoneal Amino Acid Nutrition Support

11 Chapter 11: Domain 2 — Treatments Across the Continuum: Transplant & Comorbidities

11.1 Kidney Transplant I: Candidacy, Living Donors & the Early Post-Transplant Period 11.2 Kidney Transplant II: Long-Term Care, Immunosuppressant Side Effects & Graft Protection 11.3 Diabetes Management Across CKD Stages: Glycemic Targets, Medications & MNT 11.4 GI & Cardiovascular Comorbidities: Gastroparesis, Constipation, Liver Disease, Lipids & Blood Pressure

12 Chapter 12: Domain 2 — Monitoring & Evaluation: Labs, Fluid & Nutrition Trends

12.1 Renal Laboratory Surveillance: Frequency, Target Ranges & Trending 12.2 Monitoring Fluid Balance, Blood Pressure & Cardiovascular Risk 12.3 Longitudinal Assessment of Nutritional Status & Weight Trajectories

13 Chapter 13: Domain 2 — Monitoring Dialysis Adequacy & Kinetics

13.1 Hemodialysis Adequacy: Urea Kinetic Modeling, spKt/V & URR 13.2 Peritoneal Dialysis Adequacy & Peritoneal Equilibration Test (PET) 13.3 Normalized Protein Catabolic Rate (nPCR / nPNA) Interpretation 13.4 Troubleshooting Inadequate Dialysis vs. Dietary Non-Adherence

14 Chapter 14: Domain 2 — Care Coordination, Communication & Education

14.1 Interdisciplinary Team Care, Patient Education & Counseling Ethics 14.2 Individualized & Group Education: Medicare MNT and KDE Benefits, Caregivers & Curricula 14.3 Interfacility Coordination of Care: Hospital Handoffs, Transfers, Transplant Centers & Modality Changes 14.4 Psychosocial Support & Resources: Food Assistance, Financial Programs, Rehabilitation & Peer Support

15 Chapter 15: Domain 3 — Regulations & Quality Management

15.1 CMS Conditions for Coverage: IDT, Dietitian Qualifications, Assessment & Plan-of-Care Timelines 15.2 QAPI Programs, PDSA Cycles & the ESRD Quality Incentive Program 15.3 Medicare ESRD Payment, ESRD Networks, EQRS & the Survey Measures Assessment Tool

16 Chapter 16: Domain 3 — Evidence-Based Practice: Guidelines, Research & Protocols

16.1 The KDOQI 2020 Nutrition in CKD Guideline (NKF–Academy EAL): Grades & Key Statements 16.2 KDIGO & Companion Guidelines: CKD 2024, CKD-MBD, Anemia 2026, Diabetes, BP, Lipids & AKI 16.3 Appraising Current Research: Study Designs, Bias, Statistics & Landmark Renal Trials 16.4 Clinical Protocols & Algorithms: Dietitian-Managed MBD, Anemia, Potassium & Nutrition-Support Pathways

15.2 QAPI Programs, PDSA Cycles & the ESRD Quality Incentive Program

Key Takeaways Explain This Topic AI

42 CFR 494.110 requires a data-driven QAPI program, with IDT participation, that tracks dialysis adequacy, nutritional status, mineral metabolism, anemia, vascular access, medical errors, reuse, patient satisfaction and infection control.

The ESRD Quality Incentive Program, created by MIPPA 2008 section 153(c), cuts a low-scoring facility's Medicare ESRD PPS payments by 0.5% to 2.0% for the payment year.

In the PY 2028 ESRD QIP, Hypercalcemia is a reporting measure credited for entering total uncorrected calcium values in EQRS.

CMS proposed in June 2026 to replace the Hypercalcemia reporting measure with a chronic hyperphosphatemia clinical measure starting in PY 2029; this is not final until the final rule is issued.

A PDSA cycle tests a change on a small scale first (Plan, Do, Study, Act) before adopting it facility-wide.

Last updated: September 2026

Two layers of quality in dialysis

Quality oversight in dialysis runs on two linked tracks:

Quality Assessment and Performance Improvement (QAPI) is an internal program every facility must run under the Conditions for Coverage ( 42 CFR 494.110 ).

The ESRD Quality Incentive Program (ESRD QIP) is Medicare's pay-for-performance program under section 1881(h) of the Social Security Act , added by section 153(c) of the Medicare Improvements for Patients and Providers Act of 2008 (MIPPA) .

The CSR outline lists quality improvement in Domain 3, and a task statement asks you to participate with the IDT to identify areas that need improvement and to develop, implement and evaluate plans to achieve that improvement (e.g., QAPI) .

The QAPI condition (§494.110)

The facility must "develop, implement, maintain, and evaluate an effective, data-driven" QAPI program with participation by the professional members of the IDT . The program must focus on indicators linked to better health outcomes and to preventing and reducing medical errors, and the facility must be able to show CMS evidence of it.

Required indicators (§494.110(a)(2))

The program must measure, analyze and track, at a minimum:

  • adequacy of dialysis;
  • nutritional status ;
  • mineral metabolism and renal bone disease ;
  • anemia management;
  • vascular access;
  • medical injuries and medical errors;
  • the hemodialyzer reuse program, if dialyzers are reused;
  • patient satisfaction and grievances; and

infection control, including analyzing infection trends, promoting immunization and acting to reduce future infections.

Monitoring and priorities (§494.110(b)–(c))

The facility must monitor performance continuously, act to improve it, and track results to make sure improvements last. Priorities are set by the prevalence and severity of problems, with preference for activities that affect clinical outcomes or patient safety. Problems that threaten health and safety must be corrected immediately . The regulation does not set a meeting schedule. Most facilities review QAPI data monthly , and surveyors expect regular, documented review.

What the dietitian brings to QAPI

The dietitian leads or co-leads the nutrition and mineral-metabolism indicators. Examples include the share of patients with albumin below target, phosphorus above 7.0 mg/dL, IDWG above 5%, or low nPCR. The dietitian analyzes causes and designs interventions. The CMS Measures Assessment Tool lists albumin 4.0 g/dL or higher by bromocresol green (BCG) , or the lab's normal range if bromocresol purple (BCP) is used, as the albumin outcome value, and tells facilities to set aggregate goals using their ESRD Network's targets.

The Plan-Do-Study-Act (PDSA) cycle

PDSA is the small-test-of-change method most dialysis QAPI programs use:

Plan: Define the problem with data, analyze root causes (fishbone diagram or "5 whys"), set a SMART aim and predict the result.

Do: Test the change on a small scale (one shift, one pod) and collect process and outcome data.

Study: Compare results with the prediction and the baseline.

Act: Adopt, adapt or abandon the change, then plan the next cycle.

Worked example. A monthly QAPI review shows 34% of in-center patients with phosphorus above 7.0 mg/dL.

Root causes found: binders taken at bedtime, no binders with chairside snacks, and phosphate-additive fast food bought on dialysis days.

Aim: reduce the share of Shift 1 patients with phosphorus above 7.0 mg/dL from 34% to below 20% within 8 weeks.

Do: pictorial binder-meal cards; technicians prompt binder use with chairside snacks; a 10-minute "additive detective" label session.

Study: after two monthly lab cycles, Shift 1 falls to 18%, and binder-with-meal adherence rises from 42% to 81%.

Act: adopt the protocol for all shifts and add it to staff onboarding.

The ESRD Quality Incentive Program

The ESRD QIP adjusts Medicare ESRD PPS payments based on performance. Each facility gets a Total Performance Score (TPS) from 0 to 100. A facility whose TPS falls below the minimum set for that payment year has its payments reduced for the whole year on a sliding scale, up to 2% :

  • TPS relative to the minimum Payment reduction
  • At or above the minimum None
  • 1–10 points below 0.5%
  • 11–20 points below 1.0%
  • 21–30 points below 1.5%
  • 31 or more points below 2.0%

Results are public, and facility scores also appear on Dialysis Facility Care Compare .

The PY 2028 measure set (finalized in the CY 2026 ESRD PPS rule; performance year 2026)

  • Measure Type
  • In-Center Hemodialysis CAHPS (shortened to 39 questions from PY 2028) Clinical
  • Standardized Readmission Ratio; Standardized Hospitalization Ratio; Standardized Transfusion Ratio Clinical
  • Kt/V Dialysis Adequacy measure topic (adult HD, adult PD, pediatric HD, pediatric PD) Clinical
  • Hemodialysis Vascular Access: Long-Term Catheter Rate Clinical
  • Clinical Depression Screening and Follow-Up Clinical
  • NHSN Bloodstream Infection in Hemodialysis Patients Clinical
  • Percentage of Prevalent Patients Waitlisted (PPPW) Clinical

Hypercalcemia : percentage of patient-months with a total uncorrected serum or plasma calcium value reported in EQRS Reporting

  • Medication Reconciliation (MedRec) Reporting
  • COVID-19 Vaccination Coverage Among Healthcare Personnel Reporting

Two things to know about calcium and phosphorus:

Hypercalcemia is now a reporting measure. Facilities earn credit by reporting total uncorrected calcium in EQRS. The older clinical version scored the percentage of patient-months with a 3-month rolling average uncorrected calcium above 10.2 mg/dL , and the CMS survey tool still lists that value. CMS specifies uncorrected calcium to avoid differences between albumin-correction formulas.

Proposed change: the CY 2027 ESRD PPS proposed rule (June 2026) would replace the Hypercalcemia reporting measure with a Facility-Level Percentage of Chronic Hyperphosphatemia clinical measure starting in PY 2029, and would remove the MedRec and COVID-19 vaccination reporting measures. Treat this as proposed, not final , until CMS issues the final rule.

The CY 2026 rule also removed three health-equity and social-drivers reporting measures starting in PY 2027. CMS ended the ESRD Treatment Choices payment model on December 31, 2025.

QAPI versus ESRD QIP at a glance

  • Feature QAPI (§494.110) ESRD QIP (section 1881(h))
  • Purpose Internal, continuous improvement Payment incentive and public accountability
  • Who sets the measures Facility, covering the required indicator areas CMS, through annual rulemaking
  • Consequence Survey deficiencies if the program is ineffective Payment reduction of up to 2%
  • Data Facility data, Network goals, Dialysis Facility Reports EQRS, NHSN, claims and survey data

Loading diagram... Nephrology QAPI PDSA Continuous Improvement Architecture